9 Recruiting Chronic Lymphocytic Leukemia (CLL) Phase 2 Clinical Trials
Active phase 2 studies for chronic lymphocytic leukemia (cll) enrolling across the USA. Verify eligibility and contact site coordinators.
All Chronic Lymphocytic Leukemia (CLL) studiesPhase 2 Studies for Chronic Lymphocytic Leukemia (CLL)
🔵 Active, Not Recruiting Phase2
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
📍 Stanford University Medical Center (Data collection only) — Stanford, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
📍 Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
📍 Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase2
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
📍 UT MD Anderson — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
📍 New England Cancer Specialists — Scarborough, Maine
View Study & Checklist ➔ 🟢 Recruiting Phase2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
📍 City of Hope — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase2
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
📍 Northwestern University — Evanston, Illinois
View Study & Checklist ➔ 🟢 Recruiting Phase2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
📍 Moores Cancer Center at UC San Diego /ID# 230157 — La Jolla, California
View Study & Checklist ➔